Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy effects on tumor biology before CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma
NL-OMON58491Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL), sponsored by University Medical Center Groningen. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
anti-CD19 CAR-T cell therapy
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON58491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58491.